Operative results of clinical stage I non-small cell lung cancer

Ichiro Yoshino, Masafumi Yamaguchi, Testuzo Tagawa, Seiichi Fukuyama, Toshifumi Kameyama, Atsushi Osoegawa, Yoshihiko Maehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Clinical stage (c-stage) I non-small cell lung cancer (NSCLC) is generally indicated for surgery, however, surgical exploration sometimes reveals advanced disease, thus resulting in incomplete resection. Patients and methods: A total of 645 consecutive patients were investigated in which 347 were diagnosed to have c-stage IA in 347 and 298 were diagnosed to have IB disease. All cases underwent operation and were investigated for resectability and the cause of an incomplete resection. Results: The c-Stage IA patients included 16.6% of T3/4 and 10.4% of N2 whereas clinical stage IB patients included 14.4% of T3/4 and 18.8% of N2/3. A complete resection was performed in 594 patients (91%). In 347 c-stage IA patients, the complete resection rates were 93% in adenocarcinomas (235/252), 100% in squamous cell carcinomas (76/76), and 89% in others (17/19). In 298 c-stage IB patients, the complete resection rates were 86% in adenocarcinomas (141/164), 90% in squamous cell carcinomas (90/100), and 94% in others (31/33). The 5-year survival rates of the c-stage IA and IB patients who underwent a complete resection were 66.4 and 48.3%, respectively. However, the same rates were 18.4 and 14.7% for c-stage IA and IB patients who underwent an incomplete resection. The reasons for an incomplete resection in 54 patients were malignant pleurisy in 38 (70.4%), extranodal invasion of mediastinal nodal metastasis in ten (19%), an incomplete bronchial margin in three (5.6%), and ipsilateral pulmonary metastases in two (3.7%), and ipsilateral adrenal metastasis in one (1.3%). In 13% of the c-stage IB adenocarcinomas, pleural metastasis was discovered during thoracotomy. Conclusions: Pleural dissemination was the most frequent cause of an incomplete resection, and its prevalence was high in c-stage IB adenocarcinomas.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalLung Cancer
Volume42
Issue number2
DOIs
Publication statusPublished - Nov 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Adenocarcinoma
Neoplasm Metastasis
Squamous Cell Carcinoma
Pleurisy
Thoracotomy
Survival Rate
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Yoshino, I., Yamaguchi, M., Tagawa, T., Fukuyama, S., Kameyama, T., Osoegawa, A., & Maehara, Y. (2003). Operative results of clinical stage I non-small cell lung cancer. Lung Cancer, 42(2), 221-225. https://doi.org/10.1016/S0169-5002(03)00277-0

Operative results of clinical stage I non-small cell lung cancer. / Yoshino, Ichiro; Yamaguchi, Masafumi; Tagawa, Testuzo; Fukuyama, Seiichi; Kameyama, Toshifumi; Osoegawa, Atsushi; Maehara, Yoshihiko.

In: Lung Cancer, Vol. 42, No. 2, 01.11.2003, p. 221-225.

Research output: Contribution to journalArticle

Yoshino, I, Yamaguchi, M, Tagawa, T, Fukuyama, S, Kameyama, T, Osoegawa, A & Maehara, Y 2003, 'Operative results of clinical stage I non-small cell lung cancer', Lung Cancer, vol. 42, no. 2, pp. 221-225. https://doi.org/10.1016/S0169-5002(03)00277-0
Yoshino, Ichiro ; Yamaguchi, Masafumi ; Tagawa, Testuzo ; Fukuyama, Seiichi ; Kameyama, Toshifumi ; Osoegawa, Atsushi ; Maehara, Yoshihiko. / Operative results of clinical stage I non-small cell lung cancer. In: Lung Cancer. 2003 ; Vol. 42, No. 2. pp. 221-225.
@article{2109c1d1ec6f44aca25ee68a567de0e1,
title = "Operative results of clinical stage I non-small cell lung cancer",
abstract = "Background: Clinical stage (c-stage) I non-small cell lung cancer (NSCLC) is generally indicated for surgery, however, surgical exploration sometimes reveals advanced disease, thus resulting in incomplete resection. Patients and methods: A total of 645 consecutive patients were investigated in which 347 were diagnosed to have c-stage IA in 347 and 298 were diagnosed to have IB disease. All cases underwent operation and were investigated for resectability and the cause of an incomplete resection. Results: The c-Stage IA patients included 16.6{\%} of T3/4 and 10.4{\%} of N2 whereas clinical stage IB patients included 14.4{\%} of T3/4 and 18.8{\%} of N2/3. A complete resection was performed in 594 patients (91{\%}). In 347 c-stage IA patients, the complete resection rates were 93{\%} in adenocarcinomas (235/252), 100{\%} in squamous cell carcinomas (76/76), and 89{\%} in others (17/19). In 298 c-stage IB patients, the complete resection rates were 86{\%} in adenocarcinomas (141/164), 90{\%} in squamous cell carcinomas (90/100), and 94{\%} in others (31/33). The 5-year survival rates of the c-stage IA and IB patients who underwent a complete resection were 66.4 and 48.3{\%}, respectively. However, the same rates were 18.4 and 14.7{\%} for c-stage IA and IB patients who underwent an incomplete resection. The reasons for an incomplete resection in 54 patients were malignant pleurisy in 38 (70.4{\%}), extranodal invasion of mediastinal nodal metastasis in ten (19{\%}), an incomplete bronchial margin in three (5.6{\%}), and ipsilateral pulmonary metastases in two (3.7{\%}), and ipsilateral adrenal metastasis in one (1.3{\%}). In 13{\%} of the c-stage IB adenocarcinomas, pleural metastasis was discovered during thoracotomy. Conclusions: Pleural dissemination was the most frequent cause of an incomplete resection, and its prevalence was high in c-stage IB adenocarcinomas.",
author = "Ichiro Yoshino and Masafumi Yamaguchi and Testuzo Tagawa and Seiichi Fukuyama and Toshifumi Kameyama and Atsushi Osoegawa and Yoshihiko Maehara",
year = "2003",
month = "11",
day = "1",
doi = "10.1016/S0169-5002(03)00277-0",
language = "English",
volume = "42",
pages = "221--225",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Operative results of clinical stage I non-small cell lung cancer

AU - Yoshino, Ichiro

AU - Yamaguchi, Masafumi

AU - Tagawa, Testuzo

AU - Fukuyama, Seiichi

AU - Kameyama, Toshifumi

AU - Osoegawa, Atsushi

AU - Maehara, Yoshihiko

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Background: Clinical stage (c-stage) I non-small cell lung cancer (NSCLC) is generally indicated for surgery, however, surgical exploration sometimes reveals advanced disease, thus resulting in incomplete resection. Patients and methods: A total of 645 consecutive patients were investigated in which 347 were diagnosed to have c-stage IA in 347 and 298 were diagnosed to have IB disease. All cases underwent operation and were investigated for resectability and the cause of an incomplete resection. Results: The c-Stage IA patients included 16.6% of T3/4 and 10.4% of N2 whereas clinical stage IB patients included 14.4% of T3/4 and 18.8% of N2/3. A complete resection was performed in 594 patients (91%). In 347 c-stage IA patients, the complete resection rates were 93% in adenocarcinomas (235/252), 100% in squamous cell carcinomas (76/76), and 89% in others (17/19). In 298 c-stage IB patients, the complete resection rates were 86% in adenocarcinomas (141/164), 90% in squamous cell carcinomas (90/100), and 94% in others (31/33). The 5-year survival rates of the c-stage IA and IB patients who underwent a complete resection were 66.4 and 48.3%, respectively. However, the same rates were 18.4 and 14.7% for c-stage IA and IB patients who underwent an incomplete resection. The reasons for an incomplete resection in 54 patients were malignant pleurisy in 38 (70.4%), extranodal invasion of mediastinal nodal metastasis in ten (19%), an incomplete bronchial margin in three (5.6%), and ipsilateral pulmonary metastases in two (3.7%), and ipsilateral adrenal metastasis in one (1.3%). In 13% of the c-stage IB adenocarcinomas, pleural metastasis was discovered during thoracotomy. Conclusions: Pleural dissemination was the most frequent cause of an incomplete resection, and its prevalence was high in c-stage IB adenocarcinomas.

AB - Background: Clinical stage (c-stage) I non-small cell lung cancer (NSCLC) is generally indicated for surgery, however, surgical exploration sometimes reveals advanced disease, thus resulting in incomplete resection. Patients and methods: A total of 645 consecutive patients were investigated in which 347 were diagnosed to have c-stage IA in 347 and 298 were diagnosed to have IB disease. All cases underwent operation and were investigated for resectability and the cause of an incomplete resection. Results: The c-Stage IA patients included 16.6% of T3/4 and 10.4% of N2 whereas clinical stage IB patients included 14.4% of T3/4 and 18.8% of N2/3. A complete resection was performed in 594 patients (91%). In 347 c-stage IA patients, the complete resection rates were 93% in adenocarcinomas (235/252), 100% in squamous cell carcinomas (76/76), and 89% in others (17/19). In 298 c-stage IB patients, the complete resection rates were 86% in adenocarcinomas (141/164), 90% in squamous cell carcinomas (90/100), and 94% in others (31/33). The 5-year survival rates of the c-stage IA and IB patients who underwent a complete resection were 66.4 and 48.3%, respectively. However, the same rates were 18.4 and 14.7% for c-stage IA and IB patients who underwent an incomplete resection. The reasons for an incomplete resection in 54 patients were malignant pleurisy in 38 (70.4%), extranodal invasion of mediastinal nodal metastasis in ten (19%), an incomplete bronchial margin in three (5.6%), and ipsilateral pulmonary metastases in two (3.7%), and ipsilateral adrenal metastasis in one (1.3%). In 13% of the c-stage IB adenocarcinomas, pleural metastasis was discovered during thoracotomy. Conclusions: Pleural dissemination was the most frequent cause of an incomplete resection, and its prevalence was high in c-stage IB adenocarcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0142011054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142011054&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00277-0

DO - 10.1016/S0169-5002(03)00277-0

M3 - Article

C2 - 14568690

AN - SCOPUS:0142011054

VL - 42

SP - 221

EP - 225

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -